Cargando…

Savolitinib versus crizotinib for treating MET positive non‐small cell lung cancer

BACKGROUND: The c‐MET protein, encoded by the mesenchymal‐epithelial transition factor (MET) gene, can regulate cell proliferation, migration and invasion. Studies have shown that it is one of the essential driver genes for non‐small cell lung cancer (NSCLC). Currently, several clinical studies have...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miao, Kang, Zhang, Xiaotong, Wang, Hanping, Si, Xiaoyan, Zhang, Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2023
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10151136/ https://www.ncbi.nlm.nih.gov/pubmed/36944506 http://dx.doi.org/10.1111/1759-7714.14848

Ejemplares similares

Landscape of Savolitinib Development for the Treatment of Non-Small Cell Lung Cancer with MET Alteration—A Narrative Review
por: Zhu, Xiaokuan, et al.
Publicado: (2022)

Pharmacokinetic/Pharmacodynamic Analysis of Savolitinib plus Osimertinib in an EGFR Mutation–Positive, MET-Amplified Non–Small Cell Lung Cancer Model
por: Jones, Rhys D.O., et al.
Publicado: (2023)

Use of savolitinib as neoadjuvant therapy for non–small cell lung cancer patient with MET exon 14 skipping alterations: A case report
por: Zhang, Yu, et al.
Publicado: (2022)

Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, MET-Amplified Non–Small Cell Lung Cancer: TATTON
por: Hartmaier, Ryan J., et al.
Publicado: (2023)

Mechanisms of Acquired Resistance to Savolitinib, a Selective MET Inhibitor in MET-Amplified Gastric Cancer
por: Frigault, Melanie M., et al.
Publicado: (2020)

Acquired Resistance to Osimertinib Plus Savolitinib Is Mediated by MET-D1228 and MET-Y1230 Mutations in EGFR-Mutated MET-Amplified Lung Cancer
por: Piper-Vallillo, Andrew J., et al.
Publicado: (2020)

Acquired savolitinib resistance in non-small cell lung cancer arises via multiple mechanisms that converge on MET-independent mTOR and MYC activation
por: Henry, Ryan E., et al.
Publicado: (2016)

Case Report: A Lung Adenocarcinoma With Brain Metastasis Harbored Novel MET 14 Skipping Alteration Sensitive to Savolitinib
por: Li, Jian, et al.
Publicado: (2022)

Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression
por: Chen, Rui-Lian, et al.
Publicado: (2018)

Effective treatment of MET-amplified non-small cell lung cancer patients with crizotinib: a case description
por: Tang, Mingyue, et al.
Publicado: (2023)

Effective response to crizotinib of concurrent KIF5B-MET and MET-CDR2-rearranged non-small cell lung cancer: A case report
por: Liu, Lian-Fang, et al.
Publicado: (2022)

Role of Crizotinib in previously treated non-small-cell lung cancer
por: Gupta, Sunil Kumar
Publicado: (2014)

Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer
por: Nishio, Makoto, et al.
Publicado: (2018)

NLCIPS: Non-Small Cell Lung Cancer Immunotherapy Prognosis Score
por: Song, Peng, et al.
Publicado: (2020)

Re-biopsy status among Chinese non-small-cell lung cancer patients who progressed after icotinib therapy
por: Wang, Hanping, et al.
Publicado: (2018)

Comparison of Clinical Efficacy of Alectinib Versus Crizotinib in ALK-Positive Non-Small Cell Lung Cancer: A Meta-Analysis
por: Tang, Hao, et al.
Publicado: (2021)

Phase Ia/Ib Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors:  Safety, Efficacy, and Biomarkers
por: Wang, Yakun, et al.
Publicado: (2022)

Chidamide increases the sensitivity of Non-small Cell Lung Cancer to Crizotinib by decreasing c-MET mRNA methylation
por: Ding, Nan, et al.
Publicado: (2020)

Circulating tumour DNA biomarkers in savolitinib-treated patients with non-small cell lung cancer harbouring MET exon 14 skipping alterations: a post hoc analysis of a pivotal phase 2 study
por: Yu, Yongfeng, et al.
Publicado: (2022)

Case Report: Dramatic Response to Crizotinib in a Patient With Non-Small Cell Lung Cancer Positive for a Novel ARL1-MET Fusion
por: Ma, Qing, et al.
Publicado: (2022)

Alectinib versus crizotinib in ALK‐positive advanced non‐small cell lung cancer and comparison of next‐generation TKIs after crizotinib failure: Real‐world evidence
por: Wang, Yurong, et al.
Publicado: (2022)

Successful treatment with osimertinib and its subsequent resistance mechanism in a patient with non-small-cell lung cancer harboring acquired EGFR T790M mutation after recovery from AC0010-induced interstitial lung disease
por: Wang, Hanping, et al.
Publicado: (2019)

Crizotinib in the treatment of non-small-cell lung carcinoma
por: Płużański, Adam, et al.
Publicado: (2013)

The potential role of HGF-MET signaling and autophagy in the war of Alectinib versus Crizotinib against ALK-positive NSCLC
por: Huang, Xing
Publicado: (2018)

Heterogeneous responses and resistant mechanisms to crizotinib in ALK‐positive advanced non‐small cell lung cancer
por: Kang, Jin, et al.
Publicado: (2018)

Real-World Data of Different Immune Checkpoint Inhibitors for Non-Small Cell Lung Cancer in China
por: Miao, Kang, et al.
Publicado: (2022)

Dramatic response to neoadjuvant savolitinib in marginally resectable lung adenocarcinoma with MET exon 14 skipping mutation: A case report and literature review
por: Tian, Jiangfang, et al.
Publicado: (2022)

Treatment with or without bevacizumab as a first‐line and maintenance therapy for advanced non‐squamous non‐small cell lung cancer: A retrospective study
por: Jun, Ni, et al.
Publicado: (2020)

Relationship between the efficacy of immunotherapy and characteristics of specific tumor mutation genes in non‐small cell lung cancer patients
por: Song, Peng, et al.
Publicado: (2020)

Peripheral Blood Lymphocyte Subsets Predict the Efficacy of Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer
por: Miao, Kang, et al.
Publicado: (2022)

Savolitinib: A Promising Targeting Agent for Cancer
por: Lee, Tae Seung, et al.
Publicado: (2023)

Case report: Savolitinib induced severe adverse reactions resembling septic shock in an HIV-1–positive patient with advanced non-small cell lung cancer
por: Xiong, Ye, et al.
Publicado: (2023)

Case Report: Prompt Response to Savolitinib in a Case of Advanced Gastric Cancer With Bone Marrow Invasion and MET Abnormalities
por: Ye, Wen, et al.
Publicado: (2022)

Dramatic response and acquired resistance to savolitinib in advanced intrahepatic cholangiocarcinoma with MET amplification: a case report and literature review
por: Zhou, Kexun, et al.
Publicado: (2023)

Single‐center study to determine the safety and efficacy of CT‐707 in Chinese patients with advanced anaplastic lymphoma kinase‐rearranged non‐small‐cell lung cancer
por: Song, Peng, et al.
Publicado: (2020)

Long-Term Efficacy, Safety, and Subgroup Analysis of Savolitinib in Chinese Patients With NSCLCs Harboring MET Exon 14 Skipping Alterations
por: Lu, Shun, et al.
Publicado: (2022)

Corrigendum: Peripheral blood lymphocyte subsets predict the efficacy of immune checkpoint inhibitors in non– small cell lung cancer
por: Miao, Kang, et al.
Publicado: (2022)

Neoadjuvant Savolitinib targeted therapy stage IIIA-N2 primary lung adenocarcinoma harboring MET Exon 14 skipping mutation: A case report
por: Fu, Meng, et al.
Publicado: (2022)

Crizotinib in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer versus chemotherapy as a first-line treatment
por: Zhou, Jianya, et al.
Publicado: (2018)

Cost-Effectiveness Analysis Of Ceritinib And Alectinib Versus Crizotinib In The Treatment Of Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer
por: Liu, Maobai, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_qtfmvq7c1vher11fbvpqslhagv